Andrea Lobo,  —

Oral carnitine supplements were well tolerated and blood levels of the molecule increased in people with pulmonary arterial hypertension (PAH), a pilot study shows. Carnitine transports fatty acids — the building blocks of fatty molecules…

Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials. “Efficacy and risk assessment results suggest that [Adempas] can be beneficial for…

The European Commission has granted orphan medicinal product designation to Cereno Scientific’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five per 10,000 individuals in the European Union (EU), or…

Winrevair (sotatercept-csrk), Merck’s injection therapy for adults with pulmonary arterial hypertension (PAH), has been approved in the European Union, as well as in Iceland, Liechtenstein, and Norway. The approval from the European Commission specifically covers Winrevair when used in combination with other PAH therapies to improve…

The protein asporin was identified as a possible biomarker of disease severity and to be protective in pulmonary arterial hypertension (PAH), a study suggests that used lung and blood samples from people with the disease. The protein was increased in PAH patients and correlated with reduced disease severity. In…

People with interstitial lung disease face higher healthcare resource utilization (HCRU) and increased medical costs if they are also diagnosed with pulmonary hypertension (PH-ILD), according to a U.S. study. Factors associated with increased burden and costs include a significantly higher need for inpatient care, longer hospitalizations,  as well as…

Children of cigarette-smoking parents are at greater risk of developing pulmonary arterial hypertension (PHA) within a year after birth, according to a new study by researchers in Iran. Specifically, almost half of babies exposed to parental cigarette smoke were diagnosed with PAH, while none of the children with nonsmoking…

Two molecules, 5-hydroxyindoleacetic acid (5-HIAA) and insulin-like growth factor 1 (IGF-1), showed a potential to diagnose pulmonary hypertension  early in children with congenital heart disease based on their levels in blood and urine samples examined in a study. 5-HIAA is the main product of the breakdown of serotonin, a…

Healthcare costs were found to be more than eight times higher for people with pulmonary arterial hypertension (PAH) compared with patients without the disease in a real-world study — which contributed to the greater economic burden seen for those being treated for PAH. These costs were mainly driven by…

Gemcitabine, a chemotherapy given to treat solid cancers, may drive the onset of pulmonary arterial hypertension (PAH) in patients or worsen existing PAH, a recent study reports. Stopping treatment with gemcitabine, with or without a subsequent PAH-approved treatment, led to clinical improvement or disease stabilization for a majority…

Treatment with Revatio (sildenafil) at a higher dose than the recommended and previously approved doses did not significantly increase mortality of adults with pulmonary arterial hypertension (PAH). That’s according to results from the Phase 3b/4 AFFILIATE trial (NCT02060487), which compared three treatment doses, each given three times…

Levels of fractional exhaled nitric oxide (FeNO) — a measure of how much nitric oxide a person exhales — may be used as a diagnostic tool for severe disease in people with idiopathic pulmonary arterial hypertension (iPAH), a study has found. Specifically, patients with FeNO levels lower than 23…